250 related articles for article (PubMed ID: 27177843)
1. Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48/45) in mice after disruption of disulphide bonds - evaluating effect of interferon-γ-inducible lysosomal thiol reductase.
Merino KM; Bansal GP; Kumar N
Immunology; 2016 Aug; 148(4):433-47. PubMed ID: 27177843
[TBL] [Abstract][Full Text] [Related]
2. Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.
Datta D; Bansal GP; Grasperge B; Martin DS; Philipp M; Gerloff D; Ellefsen B; Hannaman D; Kumar N
Vaccine; 2017 Dec; 35(50):7049-7056. PubMed ID: 29132995
[TBL] [Abstract][Full Text] [Related]
3. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
4. Long synthetic peptides encompassing the Plasmodium falciparum LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice.
Perlaza BL; Sauzet JP; Balde AT; Brahimi K; Tall A; Corradin G; Druilhe P
Eur J Immunol; 2001 Jul; 31(7):2200-9. PubMed ID: 11449374
[TBL] [Abstract][Full Text] [Related]
5. A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli.
Chowdhury DR; Angov E; Kariuki T; Kumar N
PLoS One; 2009 Jul; 4(7):e6352. PubMed ID: 19623257
[TBL] [Abstract][Full Text] [Related]
6. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody.
Lennartz F; Brod F; Dabbs R; Miura K; Mekhaiel D; Marini A; Jore MM; Søgaard MM; Jørgensen T; de Jongh WA; Sauerwein RW; Long CA; Biswas S; Higgins MK
Nat Commun; 2018 Sep; 9(1):3822. PubMed ID: 30237518
[TBL] [Abstract][Full Text] [Related]
8. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.
Kaba SA; McCoy ME; Doll TA; Brando C; Guo Q; Dasgupta D; Yang Y; Mittelholzer C; Spaccapelo R; Crisanti A; Burkhard P; Lanar DE
PLoS One; 2012; 7(10):e48304. PubMed ID: 23144750
[TBL] [Abstract][Full Text] [Related]
9. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.
Theisen M; Jore MM; Sauerwein R
Expert Rev Vaccines; 2017 Apr; 16(4):329-336. PubMed ID: 28043178
[TBL] [Abstract][Full Text] [Related]
10. Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice.
Outchkourov NS; Roeffen W; Kaan A; Jansen J; Luty A; Schuiffel D; van Gemert GJ; van de Vegte-Bolmer M; Sauerwein RW; Stunnenberg HG
Proc Natl Acad Sci U S A; 2008 Mar; 105(11):4301-5. PubMed ID: 18332422
[TBL] [Abstract][Full Text] [Related]
11. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.
Kundu P; Semesi A; Jore MM; Morin MJ; Price VL; Liang A; Li J; Miura K; Sauerwein RW; King CR; Julien JP
Nat Commun; 2018 Oct; 9(1):4458. PubMed ID: 30367064
[TBL] [Abstract][Full Text] [Related]
12. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
[TBL] [Abstract][Full Text] [Related]
13. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
Baldwin SL; Roeffen W; Singh SK; Tiendrebeogo RW; Christiansen M; Beebe E; Carter D; Fox CB; Howard RF; Reed SG; Sauerwein R; Theisen M
Vaccine; 2016 Apr; 34(19):2207-15. PubMed ID: 26994314
[TBL] [Abstract][Full Text] [Related]
14. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
Front Immunol; 2020; 11():606266. PubMed ID: 33505395
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human antibodies specific for the Pfs48/45 protein of the malaria parasite Plasmodium falciparum.
Roeffen WF; Raats JM; Teelen K; Hoet RM; Eling WM; van Venrooij WJ; Sauerwein RW
J Biol Chem; 2001 Jun; 276(23):19807-11. PubMed ID: 11279092
[TBL] [Abstract][Full Text] [Related]
16. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania.
Bousema T; Roeffen W; Meijerink H; Mwerinde H; Mwakalinga S; van Gemert GJ; van de Vegte-Bolmer M; Mosha F; Targett G; Riley EM; Sauerwein R; Drakeley C
PLoS One; 2010 Nov; 5(11):e14114. PubMed ID: 21124765
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe.
Paul NH; Vengesai A; Mduluza T; Chipeta J; Midzi N; Bansal GP; Kumar N
Acta Trop; 2016 Nov; 163():103-8. PubMed ID: 27491342
[TBL] [Abstract][Full Text] [Related]
18. Conformational instability governed by disulfide bonds partitions the dominant from subdominant helper T-cell responses specific for HIV-1 envelope glycoprotein gp120.
Nguyen HN; Steede NK; Robinson JE; Landry SJ
Vaccine; 2015 Jun; 33(25):2887-96. PubMed ID: 25944298
[TBL] [Abstract][Full Text] [Related]
19. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
Datta D; Bansal GP; Gerloff DL; Ellefsen B; Hannaman D; Kumar N
Vaccine; 2017 Jan; 35(2):264-272. PubMed ID: 27912985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
